好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Mild Behavioral Impairment is Associated with Postmortem Alzheimer’s Disease (AD) Neuropathology
Aging, Dementia, and Behavioral Neurology
P7 - Poster Session 7 (8:00 AM-9:00 AM)
13-003

To examine the association between mild behavioral impairment (MBI), neuropsychiatric symptoms (NPS), and postmortem AD and cerebrovascular neuropathology.

NPS are frequently observed in AD and related dementias. We have reported associations of NPS, including MBI, with cognitive and biomarker measures. We sought to extend our study to the outcome of postmortem neuropathology.

This study included 522 participants from a prospective population-based cohort, whose last visit was within 5 years of death, with NPS data (Neuropsychiatric Inventory Questionnaire [NPI-Q], Beck Depression Inventory II [BDI], Beck Anxiety Inventory [BAI]), AD neuropathology data (Braak stage, Thal phase, CERAD neuritic plaques score), and cerebrovascular neuropathology data (Kalaria score). Linear regression models were used for the outcomes of Braak and Kalaria. Proportional odds logistic regression models were run for the outcomes of Thal and CERAD. Models were run using number of visits with NPS present (adjusted for total number of visits), MBI TTV (defined as having MBI based on NPI-Q for at least two-thirds of study visits [TTV] for those with 2+ visits), and with each NPI-Q (present/absent) variable, BDI, BAI, and MBI (defined as having at least one NPI-Q variable indicated) at last visit before death as predictors. All models were adjusted for age at last visit, sex, and education.

Mean (SD) age was 86.2 (6.3) years at last visit; 42% were female. Having MBI TTV was associated with higher CERAD (OR=1.60, 95%CI=1.09-2.35) and higher Thal (OR=1.55, 95%CI=1.03-2.32). Number of visits with NPS and MBI status at last visit only were both associated with higher Braak, CERAD, and Thal scores. The latter varied by specific NPS considered. No associations of MBI/NPS were observed with Kalaria.

MBI/NPS are associated with the neuropathological measures of Braak, CERAD, and Thal, but not Kalaria, suggesting they might be more related to AD than cerebrovascular neuropathology.

Authors/Disclosures
Yonas E. Geda, MD (Barrow Neurological Institute)
PRESENTER
The institution of Dr. Geda has received research support from NIH.
Jeremy Syrjanen Jeremy Syrjanen has nothing to disclose.
Janina Krell-Roesch, PhD (Karlsruhe Institute of Technology) Dr. Krell-Roesch has nothing to disclose.
Walter Kremers The institution of Walter Kremers has received research support from NIH. The institution of an immediate family member of Walter Kremers has received research support from NIH.
Julie A. Fields, PhD (Mayo Clinic) The institution of Dr. Fields has received research support from National Institutes of Health. The institution of Dr. Fields has received research support from Patient-Centered Outcomes Research Institute.
Melissa Murray, PhD (Mayo Clinic) Dr. Murray has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Avid Radiopharmaceuticals. The institution of Dr. Murray has received research support from National Institute on Aging. The institution of Dr. Murray has received research support from Alzheimer's Association. The institution of Dr. Murray has received research support from Chan Zuckerberg Initiative.
Aivi Nguyen (Mayo Clinic) Aivi Nguyen has nothing to disclose.
Ross Reichard Ross Reichard has nothing to disclose.
Dennis W. Dickson, MD (Mayo Clinic) Dr. Dickson has nothing to disclose.
Darren Rothberg Mr. Rothberg has nothing to disclose.
Jonathan Graff-Radford, MD, FAAN Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. Dr. Graff-Radford has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Open evidence . The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Cognition therapeutics. Dr. Graff-Radford has received personal compensation in the range of $5,000-$9,999 for serving as a Faculty Member with IMPACT AD .
David S. Knopman, MD, FAAN (Mayo Clinic) Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic) Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
Maria Vassilaki, MD, PhD (Mayo Clinic, Department of Quantitative Health Sciences) Dr. Vassilaki has stock in Abbott Laboratories. Dr. Vassilaki has stock in Johnson and Johnson. Dr. Vassilaki has stock in Medtronic. Dr. Vassilaki has stock in Amgen. Dr. Vassilaki has stock in AbbVie. Dr. Vassilaki has stock in Merck. The institution of Dr. Vassilaki has received research support from NIH. The institution of Dr. Vassilaki has received research support from European Union/ St. Anne's University Hospital Brno, Czech Republic. The institution of an immediate family member of Dr. Vassilaki has received research support from Avobis Bio, LLC.